BIGGIOGGERO, MARTINA
BIGGIOGGERO, MARTINA
Dipartimento di Scienze Cliniche e di Comunità
The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
2022 E.G. Favalli, A. Gobbini, M. Bombaci, G. Maioli, M. Biggioggero, E. Pesce, A. Favalli, M. Martinovic, T. Fabbris, E. Marchisio, A. Bandiera, A. Gori, S. Abrignani, R. Grifantini, R. Caporali
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations
2022 A. Favalli, E.G. Favalli, A. Gobbini, E. Zagato, M. Bombaci, G. Maioli, E. Pesce, L. Donnici, P. Gruarin, M. Biggioggero, S. Curti, L. Manganaro, E. Marchisio, V. Bevilacqua, M. Martinovic, T. Fabbris, M.L. Sarnicola, M. Crosti, L. Marongiu, F. Granucci, S. Notarbartolo, A. Bandera, A. Gori, R. De Francesco, S. Abrignani, R. Caporali, R. Grifantini
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic
2021 E.G. Favalli, G. Maioli, M. Biggioggero, R. Caporali
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab : results from the Italian GISEA registry
2021 M. Sebastiani, V. Venerito, S. Bugatti, C. Bazzani, M. Biggioggero, L. Petricca, R. Foti, A. Bortoluzzi, S. Balduzzi, E. Visalli, B. Frediani, A. Manfredi, E. Gremese, E. Favalli, F. Iannone, G. Ferraccioli, G. Lapadula
Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights
2021 M.G. Raimondo, M. Biggioggero, L.A. Coletto, A. Ramming, R. Caporali, E.G. Favalli
Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors
2020 C. Bodio, C. Grossi, F. Pregnolato, E.G. Favalli, M. Biggioggero, A. Marchesoni, A. Murgo, M. Filippini, P. Migliorini, R. Caporali, R. Pellerito, F. Ciccia, P. Sarzi-Puttini, F. Perosa, G. Paolazzi, I. Hollan, K. Bendtzen, P.L. Meroni, M.O. Borghi
Baricitinib for COVID-19: a suitable treatment?
2020 E.G. Favalli, M. Biggioggero, G. Maioli, R. Caporali
Role of antimalarials in COVID-19 : observational data from a cohort of rheumatic patients
2020 E.G. Favalli, O. De Lucia, M. Biggioggero, N. Del Papa, R. Caporali
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis
2020 E.G. Favalli, S. Bugatti, C. Klersy, M. Biggioggero, S. Rossi, O. De Lucia, F. Bobbio-Pallavicini, A. Murgo, S. Balduzzi, R. Caporali, C. Montecucco
Is there really room for anti-rheumatic drugs in the treatment of COVID-19?
2020 E.G. Favalli, F. Ingegnoli, M. Biggioggero, R. Caporali
Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients
2020 E.G. Favalli, F. Conti, C. Selmi, F. Iannone, R. Bucci, F. D'Onofrio, G. Carlino, L. Santo, A. Semeraro, C. Zuccaro, S. D'Angelo, F. Atzeni, F. Marino, S. Monti, G.M. Guidelli, F.R. Spinelli, M. Biggioggero, R. Caporali
The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors
2019 M. Biggioggero, F. Mesina, E.G. Favalli
Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis
2019 C. Crotti, M. Biggioggero, A. Becciolini, E. Agape, E.G. Favalli
Sex and Management of Rheumatoid Arthritis
2019 E.G. Favalli, M. Biggioggero, C. Crotti, A. Becciolini, M.G. Raimondo, P.L. Meroni
Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects
2019 C. Crotti, E. Agape, A. Becciolini, M. Biggioggero, E.G. Favalli
Tocilizumab in the treatment of rheumatoid arthritis : An evidence-based review and patient selection
2019 M. Biggioggero, C. Crotti, A. Becciolini, E.G. Favalli
The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept : Retrospective analysis of a local registry
2018 E.G. Favalli, A. Becciolini, M. Biggioggero, I. Bertoldi, C. Crotti, M.G. Raimondo, A. Marchesoni
Sarilumab : patient-reported outcomes in rheumatoid arthritis
2018 C. Crotti, M. Biggioggero, A. Becciolini, E.G. Favalli
The management of first-line biologic therapy failures in rheumatoid arthritis : current practice and future perspectives
2017 E.G. Favalli, M.G. Raimondo, A. Becciolini, C. Crotti, M. Biggioggero, R. Caporali
Spotlight on mavrilimumab for the treatment of rheumatoid arthritis : Evidence to date
2017 C. Crotti, M.G. Raimondo, A. Becciolini, M. Biggioggero, E.G. Favalli